



61

RCE \$1600

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Subsection (b) of 35 USC §132, effective on May 29, 2000,  
provides for continued examination of an utility or plant application  
filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/674,800
Filing Date	November 06, 2000
First Named Inventor	Thomas STRÜNGMANN
Group Art Unit	1615
Examiner Name	Tran, Susan T.
Attorney Docket Number	4271-29RCE

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000 applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. **Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on. (Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other

**BEST AVAILABLE COPY**

**RECEIVED**  
JAN 07 2004  
TECH CENTER 1600/2900

2. **Miscellaneous**

- a. ☐ Suspension of action of the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed three months; Fee under 37 C.F.R. § 1.17(I) required)
- b. ☐ Other

**Fees**

3.

The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No.: 03-2412.
- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☐ Extension of time fee (37C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Small Entity Status is being claimed for this application.
- vi. ☐ Other
- b. ☒ Check in the amount of \$770.00 enclosed.
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Howard R. Jaeger	Registration No. (Attorney/Agent)	31,376
Signature	<i>Howard R. Jaeger</i>	Date	December 31, 2003

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on: December 31, 2003

Name (Print/Type)	Howard R. Jaeger	Date	December 31, 2003
Signature	<i>Howard R. Jaeger</i>		

770.00  
09674800  
00000106  
CNGUYEN  
01/05/2004  
01 FC:1601



Attorney Docket No. 4271-29RCE

RECEIVED  
JAN 07 2004  
TECH CENTER 1600/2900

## FILING FEE COMPUTATION SHEET

*Submit an original and a duplicate for fee processing*

Dated: December 31, 2003

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In re RCE Application of: **Thomas STRÜNGMANN**  
For: **Transdermal Therapeutic System for the Administration of  
Candesartan**  
Parent Serial No.: **09/674,800**

BEST AVAILABLE COPY

The filing fee has been calculated as shown below:

FOR:	Col. 1	Col. 2	SMALL ENTITY	OTHER THAN SMALL ENTITY
	# FILED	# EXTRA		
BASIC FEE			\$385	\$770
TOTAL CLAIMS	<u>19</u> - 20 =	<u>0</u>	x 9 = \$	x 18 = \$
INDEPENDENT CLAIMS	<u>2</u> - 3 =	<u>0</u>	x 43 = \$	x 86 = \$
<input type="checkbox"/> MULTIPLE DEPENDENCY			+\$145 = \$	+290 \$
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2			TOTAL: \$	\$ 770

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re RCE Application of

Thomas STRÜNGMANN

Parent Serial No.: 09/674,800

Parent Filed: November 06, 2000

For: Transdermal Therapeutic System  
for the Administration of  
Candesartan

Check box if applicable:

☐ DUPLICATE

**GENERAL AUTHORIZATION FOR PAYMENT OF FEES  
AND PETITIONS FOR EXTENSIONS OF TIME**

*Submit an original and a duplicate for fee processing*

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**BEST AVAILABLE COPY**


Sir:

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 03-2412

- [X] Any filing fees required under 37 CFR §1.16.
- [X] Any patent application processing fees under 37 CFR §1.17 not otherwise paid by check.
- [X] The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.
- [X] Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By



Howard R. Jaeger  
Reg. No. 31,376  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: December 31, 2003



Attorney Docket # 4271-29RCE

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Thomas STRÜNGMANN et al.

Serial No.: 09/674,800

Filed: concurrently as 37 C.F.R. 1.114 RCE Application

For: Transdermal Therapeutic System for the  
Administration of Candesartan

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**BEST AVAILABLE COPY**

**PRELIMINARY AMENDMENT**

SIR:

Prior to examination of the above-identified application, amend the application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 9 of this paper.